Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes

Bone Marrow Transplantation volume 59, pages 422–424 (2024)Cite this article

Subjects

T-cell lymphoblastic leukaemia/lymphoma (T-ALL/LBL), a malignant and highly aggressive disease with a poor prognosis. Current treatment strategies still rely on ALL-type chemotherapy combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) during first complete remission (CR1) in patients with high-risk (HR) features, as well as in those in second CR (CR2) or beyond [1]. Presently, limited data exist on the outcomes of allo-HSCT for T-ALL/LBL, particularly in HR patients. Therefore, we aimed to explore the influencing factors of survival and prognosis of patients with HR T-ALL/LBL who received allo-HSCT.

Between 2010 and 2022, a total of 166 T-ALL/LBL patients were identified at the Zhujiang Hospital of Southern Medical University. Among them, 56 patients (age ≥ 16) with HR features who received allo-HSCT were included in this study. The Pre-transplantation treatment procedures outcome measures were shown in Supplementary Methods.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

All data included in this study are available upon request from the corresponding author.

References

  1. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114:5136–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22:4075–86.

    Article  CAS  Google Scholar 

  3. Yang L, Tan Y, Shi J, Zhao Y, Zhu Y, Hu Y, et al. Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma. Bone Marrow Transplant. 2020;55:2056.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bazarbachi A, Labopin M, Angelucci E, Gülbas Z, Ozdogu H, Arat M, et al. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2020;26:936–42.

    Article  CAS  Google Scholar 

  5. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006;108:465–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Eckert C, Parker C, Moorman AV, Irving JAE, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175–89. (1990)

    Article  CAS  PubMed  Google Scholar 

  7. Liang D, Wei C, Zhang X, Yang J, Zheng Y, Du J, et al. Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2021;62:2521–5.

    Article  CAS  PubMed  Google Scholar 

  8. Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang M-J, Wang H-L, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3:670–80.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet. Haematol. 2020;7:e157–e167.

    Article  PubMed  Google Scholar 

  10. Wei C, Zhang X, Liang D, Yang J, Du J, Yue C, et al. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Drug Design, Development and Therapy. 2021;15:4875–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155–9.

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are very grateful to all the physicians and nurses who cared for the patients in this study.

Author information

Author notes

  1. These authors contributed equally: Xiaoting Zhang, Yuyang Pang.

  2. These authors jointly supervised this work: Rui Huang, Lan Deng.

Authors and Affiliations

  1. Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, People’s Republic of China

    Xiaoting Zhang, Dan Liang & Rui Huang

  2. Department of Hematology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China

    Yuyang Pang, Shaoxin Yang, Chong Zhao & Lan Deng

  3. Department of Hematology, Huizhou Municipal Central Hospital, Huizhou, 510280, People’s Republic of China

    Cong Wei

Authors
  1. Xiaoting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuyang Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dan Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaoxin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lan Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZX, PY, HR, and DL designed the study and wrote the manuscript; WC, LD, YS, and ZC contributed to the study design. All authors provided final approval for the manuscript.

Corresponding authors

Correspondence to Rui Huang or Lan Deng.

Ethics declarations

Competing interests

Supported by the Project of Biobank (NO. YBKB202109) from Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Pang, Y., Wei, C. et al. Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes. Bone Marrow Transplant 59, 422–424 (2024). https://doi.org/10.1038/s41409-023-02182-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02182-2

Search

Advanced search

Quick links